NewcelX Ltd. (NCEL)
NASDAQ: NCEL · Real-Time Price · USD
2.970
+0.050 (1.71%)
At close: Sep 29, 2026, 4:00 PM EDT
2.900
-0.070 (-2.36%)
After-hours: Sep 29, 2026, 4:10 PM EDT
NewcelX Employees
As of December 31, 2025, NewcelX had 12 total employees, including 9 full-time and 3 part-time employees. The number of employees decreased by 3 or -20.00% compared to the previous year.
Employees
12
Change (1Y)
-3
Growth (1Y)
-20.00%
Revenue / Employee
n/a
Profits / Employee
-$222,500
Market Cap
17.16M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 12 | -3 | -20.00% | 9 | 3 |
| Dec 31, 2024 | 15 | 3 | 25.00% | 11 | 4 |
| Dec 31, 2023 | 12 | -19 | -61.29% | 12 | 0 |
| Dec 31, 2022 | 31 | -1 | -3.13% | 31 | 0 |
| Dec 31, 2020 | 32 | - | - | 28 | 4 |
Related Stocks
| Company Name | Employees |
|---|---|
| Palatin Technologies | 29 |
| Citius Pharmaceuticals | 23 |
| BioCardia | 21 |
| Lipocine | 14 |
| Kiora Pharmaceuticals | 13 |
| Tvardi Therapeutics | 12 |
| Actuate Therapeutics | 12 |
| Cellectar Biosciences | 11 |
NCEL News
- 1 day ago - NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes - GlobeNewsWire
- 5 weeks ago - NewcelX registers to sell 694K common shares for holders - TheFly
- 2 months ago - NewcelX announces pricing of $1.4M equity financing - TheFly
- 2 months ago - NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing - GlobeNewsWire
- 2 months ago - NewcelX announces Brazil patent for cell selection, enrichment technology - TheFly
- 2 months ago - NewcelX initiated with a Buy at Laidlaw - TheFly
- 2 months ago - NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board - GlobeNewsWire
- 3 months ago - NewcelX completes Type B Pre-IND meeting with FDA for NCEL-101 - TheFly